Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 100.14 -1.01 (-1.00%)
price chart
Johnson & Johnson to Remove Formaldehyde From Products
Johnson & Johnson, which makes a range of personal care products like baby shampoo, acne cream and antiwrinkle lotion, announced plans Wednesday to remove a host of potentially harmful chemicals, like formaldehyde, from its line of consumer products ...
Johnson & Johnson Removing 'Chemicals Of Concern" From Adult ...  Huffington Post
How Johnson & Johnson is cutting out toxics  GreenBiz.com
Johnson & Johnson Announces a Ban on Harmful Chemicals in Products
Johnson & Johnson made the landmark announcement this week that it would ban harmful chemicals from their products. The company has already made the pledge to remove toxic chemicals from its baby products by 2013.
The Real Lesson of Formaldehyde In Baby Shampoo  TIME
Time for companies to pledge to remove dangerous chemicals from products  Fox News
Johnson & Johnson Eyes China's Baby Market
Johnson & Johnson is rumored to be considering the acquisition of a local baby-care product vendor Shanghai Elsker in China, a move that could strengthen its foothold in the rapidly-growing Chinese baby-care market.
Johnson & Johnson Still Hates Women With Heavier Than Normal Periods
Last year the internet was in an uproar because Johnson & Johnson discontinued OB Ultra Absorbency tampons. By internet, I mean women's sites, of course.
Genmab, Johnson & Johnson agree $1.1 billion cancer deal
Janssen Biotech will make an upfront payment of $55 million for the license and Johnson & Johnson Development Corp would invest 475 million Danish crowns ($80 million) in new Genmab shares, the company said.
Genmab Surges on Johnson & Johnson Cancer Pact: Copenhagen Mover  Bloomberg
J&J grabs Genmab's promising leukemia antibody in $1.1B deal  FierceBiotech
Trials for Alzheimer's Drug Halted After Poor Results
Johnson & Johnson and Pfizer announced on Monday that they were halting development of a closely watched Alzheimer's drug after two clinical trials failed to show that it was effective in patients with mild to moderate forms of the disease.
Pfizer, J&J scrap Alzheimer's studies as drug fails  Reuters
Pfizer, J&J end development of once-promising Alzheimer's drug  The Star-Ledger - NJ.com
Johnson & Johnson unit recalls bone putty
The health regulator said certain lots of bone putty made by Johnson & Johnson unit Synthes were recalled as there was potential for the putty to catch fire if it came in contact with electrosurgical cautery systems during surgery.
Johnson & Johnson says it has tentative settlement with Justice officials over ...
Johnson & Johnson has “an agreement in principle'' with the U.S. Justice Department to settle claims it inappropriately marketed the antipsychotic drug Risperdal and two other medicines, according to documents filed yesterday with federal securities ...
Johnson & Johnson makes $50 million milestone payment to California-based ...
Janssen Biotech, part of Johnson & Johnson, will pay a $50 million milestone payment to Pharmacyclics, its collaborator on a new treatment for mantle cell lymphoma.
Here Are The Allegations That Spurred J&J To Pay A $181 Million Settlement ...
Johnson & Johnson said Thursday it would pay $181 million to end claims by 36 states over its marketing of the blockbuster antipsychotic drug Risperdal.
Johnson Johnson subsidiary to pay record amount to settle off-label ...  Seattle Post Intelligencer (blog)
J&J Will Pay $181 Million to Settle Risperdal Ad Claims  Bloomberg